Common Inborn Errors of Metabolism in the Caribbean Population
There is no specific evidence available regarding the common inborn errors of metabolism (IEMs) in the Caribbean population, as none of the provided studies address this geographic region or its unique genetic epidemiology.
Critical Evidence Gap
The provided evidence focuses primarily on:
- General newborn screening guidelines for IEMs in the United States 1
- Diagnostic approaches in developing countries 2
- Global screening variability 3
- Clinical presentations in various settings 4, 5
None of these sources provide Caribbean-specific data on IEM prevalence, incidence, or the most commonly encountered disorders in this population.
What We Know About IEMs Generally
While Caribbean-specific data is absent, the general framework for understanding IEMs includes:
Most Commonly Screened Disorders Globally
- Congenital hypothyroidism and phenylketonuria are the two IEMs included in most screening programs worldwide 3
- The incidence of each IEM varies significantly between countries and even between regions within the same country 3
- Global prevalence of IEMs collectively is estimated at 50.9 per 100,000 live births 6
Categories of IEMs Typically Detected
Based on expanded newborn screening programs 1:
- Fatty acid oxidation disorders (e.g., VLCAD deficiency)
- Amino acid disorders (e.g., maple syrup urine disease, homocystinuria)
- Organic acid disorders (e.g., propionic acidemia, 3-methylcrotonyl-CoA carboxylase deficiency)
- Urea cycle disorders (e.g., argininosuccinic lyase deficiency)
Critical Clinical Caveat
The Caribbean population likely has a unique genetic epidemiology influenced by African, European, Asian, and indigenous ancestry patterns that would affect IEM prevalence. Without population-specific screening data or epidemiological studies from Caribbean nations, any attempt to identify "common" IEMs would be speculative and potentially misleading for clinical practice.
Practical Approach for Caribbean Healthcare Settings
Given the evidence gap, clinicians should:
- Implement basic newborn screening for at minimum congenital hypothyroidism and phenylketonuria, as these are universally screened 3
- Utilize low-technology screening methods available in average clinical chemistry laboratories, as recommended for resource-limited settings 2
- Maintain high clinical suspicion for IEMs presenting with: developmental delay, neurological impairment, metabolic acidosis, hypoglycemia, hyperammonemia, and organ dysfunction 7
- Establish regional referral centers for confirmatory testing rather than attempting comprehensive screening at every facility 2
The absence of Caribbean-specific data represents a significant knowledge gap that requires dedicated epidemiological research and newborn screening program data collection to determine the actual burden and spectrum of IEMs in this population.